<p><span ><strong><u>ANAEMIA IN CHRONIC KIDNEY DISEASE</u></strong></span></p><p style="margin-left:0cm;text-align:justify;"><span >Anaemia develops early in the course of Chronic Kidney Disease (CKD) and is nearly universal in patients with CKD stage 5 (End-stage kidney&nbsp;disease).The&nbsp;prevalence&nbsp;of&nbsp;anaemia&nbsp;at&nbsp;higher&nbsp;levels&nbsp;of&nbsp;glomerular filtration&nbsp;rate&nbsp;(GFR)&nbsp;(i.e.&nbsp;CKD&nbsp;stage&nbsp;1-2)&nbsp;is&nbsp;relatively&nbsp;low&nbsp;in&nbsp;individuals&nbsp;from the general population. Anaemia of CKD is primarily caused by deficiency of erythropoietin. The kidneys are the major source of erythropoietin and, as renal function declines, production of erythropoietin declines proportionately.</span></p><p style="margin-left:0cm;text-align:justify;"><span >Though erythropoietin deficiency is common among patients with anaemia&nbsp;in&nbsp;CKD,&nbsp;other&nbsp;potential causes&nbsp;and&nbsp;contributing&nbsp;disorders&nbsp;should be&nbsp;identified&nbsp;or&nbsp;excluded&nbsp;if&nbsp;initial&nbsp;evaluation&nbsp;yields&nbsp;evidence&nbsp;for&nbsp;disorders other than iron deficiency or erythropoietin deficiency. Correction of anaemia in CKD patients improves survival and quality of&nbsp;life.</span></p><h3 style="margin-left:0cm;">CAUSES</h3><ul><li>Deficiency of&nbsp;erythropoietin</li><li>Red&nbsp;cell&nbsp;destruction&nbsp;from&nbsp;microvascular&nbsp;disease from&nbsp;diabetes&nbsp;or&nbsp;hypertension</li><li>Increased gastrointestinal&nbsp;bleeding</li><li>Increased&nbsp;oxidative stress&nbsp;leading&nbsp;to&nbsp;shortened&nbsp;red&nbsp;cell&nbsp;survival</li></ul><h3 style="margin-left:0cm;">SYMPTOMS</h3><ul><li><span >(See section on 'Anaemia')</span></li></ul><p style="margin-left:0cm;"><span ><strong>SIGN</strong></span></p><ul><li><span >(See section on 'Anaemia')</span></li></ul><h3 style="margin-left:0cm;">INVESTIGATIONS</h3><ul><li>FBC</li><li>Reticulocyte&nbsp;count</li><li>Transferrin&nbsp;saturation</li><li>Serum&nbsp;ferritin</li><li>Stool occult&nbsp;blood</li></ul><h3 style="margin-left:0cm;">TREATMENT</h3><p><strong>Treatment objectives</strong></p><ul><li>To&nbsp;achieve&nbsp;and&nbsp;maintain&nbsp;a&nbsp;target-range&nbsp;Hb&nbsp;level&nbsp;of&nbsp;11-12&nbsp;g/dL</li></ul><h3 style="margin-left:0cm;">Non-pharmacological treatment</h3><ul><li><span >(See section on 'Anaemia')</span></li></ul><h3 style="margin-left:0cm;">Pharmacological treatment</h3><ol><li><span ><strong>CKD Stages&nbsp;1-2</strong></span></li></ol><p style="margin-left:0cm;"><span >1<sup>st</sup> Line Treatment Evidence Rating: [A]</span></p><ul><li>Ferrous&nbsp;sulphate, oral,&nbsp;325&nbsp;mg&nbsp;8&nbsp;hourly&nbsp;for&nbsp;4&nbsp;weeks</li></ul><ol><li><span >CKD Stages&nbsp;3-4</span></li></ol><p style="margin-left:0cm;"><span ><strong>Iron replacement</strong>: Target Hb should be 11-12 g/dL</span></p><ul><li>Ferrous sulphate, oral, 325 mg 8&nbsp;hourly</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Ferrous&nbsp;gluconate,&nbsp;oral,&nbsp;300&nbsp;mg&nbsp;8-12&nbsp;hourly.&nbsp;Evaluate after&nbsp;4-6&nbsp;weeks</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Iron sucrose, IV,&nbsp;consult&nbsp;specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Ferric sodium gluconate complex, consult&nbsp;specialist</li></ul><h3 style="margin-left:0cm;">And</h3><ul><li>Epoetin beta, SC, consult&nbsp;specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Methoxy polyethylene glycol epoetin beta (pegylated form of Epo), SC, consult&nbsp;specialist</li></ul><h3 style="margin-left:0cm;">Or</h3><p style="margin-left:0cm;">Darbepoetin alfa, SC, consult&nbsp;specialist</p><p style="margin-left:0cm;">&nbsp;</p><h3 style="margin-left:0cm;">REFERRAL CRITERIA</h3><p style="margin-left:0cm;"><span >Refer all (adults and children) patients with CKD and anaemia to a specialist or nephrologist.</span></p><p style="margin-left:0cm;">&nbsp;</p><p>&nbsp;</p>